We are Anchiano Therapeutics, a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer.
We have a partnership with ADT Pharmaceuticals around two small molecule development programs targeting oncogenic pathways, focused on RAS and PDE10/ß-catenin, respectively.
Pan-RAS Program: Oncogenic mutations in the RAS family of genes (KRAS, HRAS, and NRAS) are present in approximately 30% of cancer. RAS plays a pivotal role in signal transduction pathways leading to tumor cell proliferation and survival. Our program has identified novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation, or pan-RAS inhibition.
PDE10/ß-catenin Program: Genetic alterations in components that make up the Wnt signaling pathway, which includes APC (adenomatous polyposis coli) and β-catenin, are prevalent in a number of cancer types, occurring in upwards of 80% of colorectal cancers. Our program has identified small molecules that selectively and potently inhibit PDE10 and suppress Wnt/β-catenin signaling in preclinical models. PDE10 inhibition has been shown to down regulate β-catenin expression and inhibits polyp and tumor growth. It has potential for application in the treatment of cancer as well as spontaneous and familial polyposis syndromes.
We are located in Cambridge, Massachusetts and are publicly traded on the Nasdaq (NASDAQ: ANCN).